Clinical trials: Methylphenidate, completed
Attention-Deficit/Hyperactivity Disorder
Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate
This study will evaluate how long it takes for ADHD symptoms to improve in subjects who are judged by the Investigator to have had an inadequate response to methylphenidate therapy.
- Trial name
- NCT01106430
- Testing
- Lisdexamfetamine Dimesylate, Atomoxetine Hydrochloride
- Where
- 64 sites in United States, Belgium and 8 more
- Volunteers
- 267 people
- Sponsor
- Shire
ADHD
Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17
The main aim of this study is to see if giving LDX to children and adolescents aged 6-17 years with ADHD decreases symptoms of ADHD.
- Trial name
- NCT00763971
- Testing
- Lisdexamfetamine Dimesylate (LDX), Methylphenidate Hydrochloride
- Where
- 49 sites in Belgium, France and 8 more
- Volunteers
- 336 people
- Sponsor
- Shire
Attention-Deficit / Hyperactivity Disorder
A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder
The main purpose of this study is to evaluate long-term safety and tolerability of JNS001 at 18 to 72 mg per day in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT01357993
- Testing
- JNS001
- Where
- 29 sites in Japan
- Volunteers
- 253 people
- Sponsor
- Janssen Pharmaceutical K.K.
Attention Deficit Hyperactivity Disorder
An Effectiveness and Safety Study Evaluating OROS Methylphenidate Hydrochloride (HCl), Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder
The purpose of this study is to provide data on the effectiveness of the OROS Methylphenidate Hydrochloride (HCl) formulation compared to placebo and standard immediate-release Ritalin with respect to improving attention and…
- Trial name
- NCT00269776
- Testing
- OROS (methylphenidate HCl), Ritalin (methylphenidate)
- Sponsor
- Alza Corporation, DE, USA
Attention Deficit Hyperactivity Disorder
A Multicenter Study Comparing the Efficacy and Safety of OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder
The purpose of this study is to evaluate the efficacy and safety of OROS® Methylphenidate HCl as compared with placebo and standard immediate-release Ritalin® (taken three time per day) for the treatment of Attention Deficit…
- Trial name
- NCT00269802
- Testing
- OROS methylphenidate HCl, Ritalin
- Sponsor
- Alza Corporation, DE, USA
Attention Deficit Hyperactivity Disorder
A Long-Term Safety Study to Evaluate Methylphenidate HCL Tablets at Multiple Dose Levels in Adults With Attention Deficit Hyperactivity Disorder
The purpose of this study is to evaluate the long-term safety of methylphenidate HCL extended-release tablets at five dose levels in adults with Attention Deficit Hyperactivity Disorder (ADHD)
- Trial name
- NCT00326300
- Testing
- methylphenidate hydrochloride extended-release tablets
- Volunteers
- 560 people
- Sponsor
- McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Naltrexone, Methylphenidate Abuse
Study for Naltrexone on the Abuse Potential of Methylphenidate
The current abuse liability study aims to assess the potential for co-administration of naltrexone (NTX) to reduce the abuse potential of methylphenidate (MPH).
- Trial name
- NCT03769064
- Testing
- Methylphenidate 60 mg, Treatment Phase Sequence 4213, Treatment Phase Sequence 2134
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Avekshan LLC
Attention Deficit Hyperactivity Disorder
Study to Evaluate the Efficacy and Quality of Life of Long-Acting Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the efficacy, safety and to assess the impact of the treatment on quality of life of long-acting methylphenidate in adult participants with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT00783835
- Testing
- Long-Acting Methylphenidate
- Where
- 5 sites in Brazil
- Volunteers
- 60 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Attention Deficit/ Hyperactivity Disorder
A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder
The purpose of this study is to evaluate the efficacy of 2 fixed dosages of Prolonged Release (PR) OROS methylphenidate (54 and 72 mg/day) compared with placebo in adult patients with attention deficit/hyperactivity disorder…
- Trial name
- NCT00714688
- Testing
- prolonged release (PR) OROS methylphenidate 54 mg, prolonged release (PR) OROS methylphenidate 72 mg
- Where
- 42 sites in Belgium, Denmark and 9 more
- Volunteers
- 279 people
- Sponsor
- Janssen-Cilag International NV
Attention-Deficit/Hyperactivity Disorder (ADHD)
A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED)
The purpose of this study is to investigate the safety and efficacy of an investigational treatment for Attention Deficit Hyperactivity Disorder (ADHD) when compared to placebo.
- Trial name
- NCT00475735
- Testing
- MK0249, Concerta (methylphenidate)
- Volunteers
- 72 people
- Sponsor
- Merck Sharp & Dohme LLC
Attention Deficit Disorder With Hyperactivity
Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD and Previously Participated in MTS Trials
This study will evaluate the long-term safety of MTS in the symptomatic treatment of children aged 6-12 diagnosed with ADHD
- Trial name
- NCT00151957
- Testing
- Methylphenidate Transdermal System
- Volunteers
- 450 people
- Sponsor
- Noven Therapeutics
Attention Deficit Hyperactivity Disorder
NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)
The safety and efficacy of a chewable formulation of extended-release methylphenidate will be studied in children with ADHD
- Trial name
- NCT01654250
- Testing
- NWP09
- Where
- 9 sites in United States
- Volunteers
- 90 people
- Sponsor
- Pfizer
Attention Deficit Hyperactivity Disorder (ADHD)
NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
This is a randomized, double-blind, placebo-controlled, parallel group, Phase 3 trial to evaluate the safety and efficacy of NT0102 in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 12…
- Trial name
- NCT01835548
- Testing
- NT0102
- Where
- 4 sites in United States
- Volunteers
- 87 people
- Sponsor
- Neos Therapeutics, Inc
Attention Deficit Disorder With Hyperactivity
An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the safety and efficacy of Osmotic Release Oral System (OROS) methylphenidate in participants with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT01012622
- Testing
- Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride
- Volunteers
- 142 people
- Sponsor
- Janssen Korea, Ltd., Korea
Attention Deficit/Hyperactivity Disorder
Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)
This study will evaluate efficacy and safety of methylphenidate hydrochloride extended release compared to placebo in adult patients with childhood-onset attention deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT01259492
- Testing
- Ritalin LA 20 mg, Ritalin LA 30 mg
- Where
- 68 sites in United States, Belgium and 7 more
- Volunteers
- 725 people
- Sponsor
- Novartis Pharmaceuticals
Attention Deficit Disorder With Hyperactivity
Compliance Survey of ADHD Medication for Optimal Satisfaction (COSMOS)
The survey is designed to identify non-compliant Attention Deficit Hyperactivity Disorder (ADHD) patients who are currently on Immediate- Released Methylphenidate (IR-MPH) and observe any change in compliance after treating with…
- Trial name
- NCT00460720
- Testing
- Observational treatment compliance survey
- Volunteers
- 591 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Attention-Deficit/Hyperactivity Disorder
Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD
To assess the pharmacokinetics of a single dose of Aptensio XR® (methylphenidate hydrochloride extended-release) capsules under fed conditions in male or female children 4 to under 6 years of age with ADHD.
- Trial name
- PK003 (NCT02470234)
- Testing
- Methylphenidate HCl ER Capsules, 10 mg, Methylphenidate HCl ER Capsules, 15 mg, Methylphenidate HCl ER Capsules, 20 mg
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Attention Deficit Hyperactivity Disorder
CONCERTA Lab School Study
The purpose of this trial is to determine if the study medication, CONCERTA (methylphenidate HCl), is safe and effective in improving academic performance and behavior in children with Attention Deficit Hyperactivity Disorder…
- Trial name
- NCT00799487
- Where
- 3 sites in United States
- Volunteers
- 89 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Attention Deficit Hyperactivity Disorder
A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)
This study compared the efficacy of dex-methylphenidate extended release 20 mg versus placebo during an 8-hour laboratory classroom day.
- Trial name
- NCT00564954
- Testing
- Dex-methylphenidate hydrochloride extended-release (Focalin XR)
- Where
- 5 sites in United States
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Volunteers in Fed and Fasted State
In-clinic Crossover Study in Subjects With Two Treatments (Fed vs Fasted)
The primary purpose of this study is to assess the effect of food on the rate and extent of absorption and the overall bioavailability of a single dose of CTx-1301 50 mg trimodal tablets in healthy adult volunteers.
- Trial name
- Fed-Fast (NCT07119073)
- Testing
- Dexmethylphenidate
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Cingulate Therapeutics